Literature DB >> 7797600

Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.

I Eue1, R Zeisig, D Arndt.   

Abstract

The human histiocytic cell line U 937, which expresses a number of monocyte markers and properties, was investigated with regard to its ability to be activated for NO and tumor necrosis factor (TNF) release after treatment with alkylphosphocholines (APC) and APC liposomes. Using APC multilamellar vesicles (MLV) a clear dose-dependent increase of NO production could be demonstrated for U 937 cells, whereas the corresponding soluble substances had no effect. The time course of NO release was characterised by a peak between 2 h and 12 h and a strong decrease after 24 h. LPS caused no NO release nor the production of TNF in U 937 cells. The simultaneous incubation of the cells with lipopolysaccharide and APC or APC-MLV, led to a strong increase in TNF production. Closer investigation of the time sequence of this synergistic effect demonstrated that cells, that had first been treated with hexadecylphosphocholine (HPC)-MLV and 4 h later with lipopolysaccharide secreted significantly more TNF into the supernatants than in the experiment where both substances were added simultaneously. From these results it was concluded that APC-MLV are possibly able to act as a primer in the process of lipopolysaccharide mediated TNF induction. Furthermore, a positive influence of phorbol 12-myristate 13-acetate (PMA) on the ability of U 937 cells to produce TNF following a treatment with HPC or HPC-MLV could be observed. PMA-pretreated cells were shown to release much more TNF compared to control cells, which led to the supposition that the immunomodifying activity of APC becomes effective only in more highly differentiated cell types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797600     DOI: 10.1007/bf01225687

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

Review 1.  Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level.

Authors:  H Grunicke; J Hofmann
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

Review 2.  Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening.

Authors:  H R Maurer; P Hilgard
Journal:  Prog Exp Tumor Res       Date:  1992

3.  Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.

Authors:  M Shoji; R L Raynor; E A Fleer; H Eibl; W R Vogler; J F Kuo
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

4.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

Review 5.  Alkylphosphocholines: a new class of membrane-active anticancer agents.

Authors:  P Hilgard; T Klenner; J Stekar; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.

Authors:  R Zeisig; I Fichtner; D Arndt; S Jungmann
Journal:  Anticancer Drugs       Date:  1991-08       Impact factor: 2.248

7.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

8.  Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes.

Authors:  R K Singh; I J Fidler
Journal:  Lymphokine Cytokine Res       Date:  1993-10

9.  Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro.

Authors:  R Zeisig; M Rudolf; I Eue; D Arndt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.

Authors:  R Dummer; M Krasovec; J Röger; H Sindermann; G Burg
Journal:  J Am Acad Dermatol       Date:  1993-12       Impact factor: 11.527

View more
  6 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.

Authors:  Klaus Griewank; Caroline Gazeau; Andreas Eichhorn; Esther von Stebut
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.

Authors:  Rubén E Varela-M; Janny A Villa-Pulgarin; Edward Yepes; Ingrid Müller; Manuel Modolell; Diana L Muñoz; Sara M Robledo; Carlos E Muskus; Julio López-Abán; Antonio Muro; Iván D Vélez; Faustino Mollinedo
Journal:  PLoS Negl Trop Dis       Date:  2012-04-10

6.  Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.

Authors:  Fabio Dos Santos Nogueira; Valdir Carlos Avino; Fredy Galvis-Ovallos; Vera Lucia Pereira-Chioccola; Marcio Antonio Batistella Moreira; Ana Paula Peres Lopes Romariz; Leticia M Molla; Ingrid Menz
Journal:  Parasit Vectors       Date:  2019-02-08       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.